Artelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland
June 24 2022 - 8:30AM
Artelo Biosciences,
Inc.
(Nasdaq: ARTL), a
clinical-stage pharmaceutical company focused on modulating
lipid-signaling pathways to develop treatments for people living
with cancer, pain, and neurological conditions, announced that
Professor Saoirse O’Sullivan, Artelo’s Vice President of
Translational Sciences, has been selected for an oral presentation
at the 32nd International Cannabinoid Research Society (ICRS)
Symposium, on Sunday, June 26th. Dr. Sullivan will be presenting
pre-clinical data related to ART26.12, the Company’s lead fatty
acid binding protein 5 (FABP5) inhibitor. The Company plans to
provide a summary of the research following the presentation. The
ICRS Symposium is being held at the Bailey Allen Hall at the
National University of Ireland, Galway, from June 25-30, 2022.
“We are pleased to participate in this important annual
cannabinoid research conference and are excited to share our latest
preclinical findings in ART26.12 development,” said Gregory D.
Gorgas, President and Chief Executive Officer of Artelo
Biosciences. “ART26.12 represents an important program in Artelo’s
efforts to advance programs in cancer and cancer supportive
care.”
In addition, the Company will present the prestigious William A.
Devane Young Investigator of the Year Award at the ICRS Symposium
to an outstanding researcher on Wednesday, June 29th. Prior Young
Investigator awardees include Professor Saoirse O’Sullivan and
Doctor Martin Kaczocha, Assistant Professor in the Department of
Anesthesiology, Department of Biochemistry and Cell Biology, and
the Institute of Chemical Biology and Drug Discovery at Stony Brook
University and Scientific Advisor to Artelo Biosciences.
About the International Cannabinoid Research
SocietyThe International Cannabinoid Research
Society (ICRS) is the premier global scientific association
with more than 650 international members from 40 countries, all
active researchers in the field of endogenous, plant-derived, and
synthetic cannabinoids and related bioactive lipids. In addition to
acting as a source for impartial information on cannabis and the
cannabinoids, the main role of the ICRS is to provide an open forum
for researchers to meet and discuss their research. Interested
parties may follow @ICRS_Society on Twitter and use
#ICRS2022 for the latest meeting updates.
The ICRS William A. Devane Young Investigator of the
YearIn 2018, Artelo announced a five-year commitment to
sponsor the William A. Devane Young Investigator of the Year award
at annual ICRS Symposium. This award is a unique opportunity to
identify and showcase researchers who have shown dedication,
perseverance, and skill in endocannabinoid system research. Past
recipients, Dr. Saoirse O’Sullivan, 2016 awardee, and Dr. Martin
Kaczocha, 2017 awardee, are currently assisting Artelo in advancing
its product portfolio.
About ART26.12Fatty Acid Binding Proteins
(FABPs) are a family of intracellular proteins that chaperone
lipids including endocannabinoids and fatty acids. Various
inhibitors of FABPs may be particularly useful for the treatment of
specific cancers, neuropathic and nociceptive pain, and anxiety
disorders. ART26.12, Artelo’s lead FABP inhibitor compound, is a
selective inhibitor of FABP5. While developing our lead molecule
for Chemotherapy-Induced Peripheral Neuropathy, additional
compound(s) from our extensive library of potent and selective
inhibitors of FABPs have been identified and selected for
advancement towards regulatory-enabling studies in cancer and other
areas of high-unmet need where inhibition of FABPs show significant
promise.
About Artelo Biosciences Artelo Biosciences,
Inc. is a clinical stage pharmaceutical company dedicated to
the development and commercialization of proprietary therapeutics
that modulate lipid-signaling pathways including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, anxiety, pain, and inflammation. Led by proven
biopharmaceutical executives collaborating with highly respected
researchers and technology experts, the company applies leading
edge scientific, regulatory, and commercial discipline to develop
high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking StatementsThis press release
contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and Private Securities Litigation
Reform Act, as amended, including those relating to the Company’s
product development, clinical and regulatory timelines, market
opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth
opportunities and other statement that are predictive in nature.
These forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management’s current beliefs and
assumptions. These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
“expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,”
“potential,” “predict,” “project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s filings with the
Securities and Exchange Commission, including our ability to raise
additional capital in the future. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise, except to the extent required by
applicable securities laws.
Investor Relations Contact:Crescendo
Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Apr 2023 to Apr 2024